Skip to main content
Article
Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer.
Journal of Gastrointestinal Surgery (2020)
  • Daniel W Nelson, William Beaumont Army Medical Center
  • Clay Merritt, William Beaumont Army Medical Center
  • Shu-Ching Chang, Medical Data Research Center, Providence St. Joseph Health, Portland, OR, USA.
  • Gary Grunkemeier, Medical Data Research Center, Providence St. Joseph Health, Portland, OR, USA.
  • Scott R Steele, Cleveland Clinic
  • Melanie Goldfarb, Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Publication Date
August 3, 2020
DOI
10.1007/S11605-020-04757-6
Citation Information
Daniel W Nelson, Clay Merritt, Shu-Ching Chang, Gary Grunkemeier, et al.. "Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer." Journal of Gastrointestinal Surgery (2020)
Available at: http://works.bepress.com/gary-grunkemeier/1/